27 August 2024 in Nature Communications
Remote regulation of cells in deep tissue remains a significant challenge. Low-intensity pulsed ultrasound offers promise for in vivo therapies due to its non-invasive nature and precise control. This study uses pulsed ultrasound to control calcium influx in mammalian cells and engineers a therapeutic cellular device responsive to acoustic stimulation in deep tissue without overexpressing calcium channels or gas vesicles. Pulsed ultrasound parameters are established to induce calcium influx in HEK293 cells. Additionally, cells are engineered to express a designed calcium-responsive transcription factor controlling the expression of a selected therapeutic gene, constituting a therapeutic cellular device. The engineered sonogenetic system’s functionality is demonstrated in vivo in mice, where an implanted anti-inflammatory cytokine-producing cellular device effectively alleviates acute colitis, as shown by improved colonic morphology and histopathology. This approach provides a powerful tool for precise, localized control of engineered cells in deep tissue, showcasing its potential for targeted therapeutic delivery.
16 May 2025 in IEEE Transactions on Ultrasonics
Sonogenetics is developing into a powerful tool in synthetic biology. The coupling of ultrasound with genetically engineered effectors enables non-invasive and precise control of cellular and molecular processes. Building on established techniques such as optogenetics, it overcomes the limits of tissue penetration and invasiveness, making it a promising tool for both research and therapeutic applications. Recent advances in acoustic contrast agents, such as microbubbles and gas vesicles, have improved the mechanical effects of ultrasound on cells, extending its application to various biological systems. This review highlights recent advances and challenges, such as standardization of parameters and understanding of underlying mechanisms, and outlines future directions for ultrasound-guided cellular control.
31 January 2026 in Nature Communications
Cells regulate processes through protein interaction networks. Most chemically induced dimerization (CID) systems respond to exogenous molecules, limiting integration with endogenous signaling. Here, we repurpose nuclear receptor (NR) ligand-binding domains (LBDs) and coactivators to develop hormone- or clinically approved drug-responsive CIDs. Using the LBDs of TRβ, VDR, RARγ, ERβ, and GR2 with a TIF2 coactivator peptide, we constructed CIDs responsive to triiodothyronine, vitamin D, retinoic acid, estrogen, cortisol, and their antagonists. These CIDs enable two-input transcriptional switches for gene regulation. Furthermore, we design hormone-responsive liquid-liquid phase-separated (LLPS) condensates that strongly amplify transcription when exceeding a critical interaction threshold. These functional LLPS condensates provide a tunable platform for transcriptional control with up to several hundred-fold activation. Our findings offer an approach for integrating synthetic biology with physiological signaling, advancing applications in gene circuits, biosensing, and therapeutics through ligand-controlled LLPS formation.
25 September 2026 in Nature Communications